ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting

ERYTECH announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).

Menu